[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364154-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364154-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","discovery-of-highly-efficacious-crbn-based-kras-degraders-targeting-cancers-with-kras-g12d-and-g12v-mutations","Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations","","KRAS G12D and G12V mutants comprise over half of human cancers with mutated KRAS, making targeted therapies highly sought after. The work presents design, synthesis, and evaluation of PROTAC KRAS degraders using a new cereblon ligand, leading to CW-10201. CW-10201 induces low-nanomolar degradation of KRASG12D and KRASG12V mutants in cells, achieving IC50 values of 2–4 nM for inhibition of cancer cell growth, and shows strong pharmacokinetic and pharmacodynamic performance in mice. In xenograft models, it supports tumor regression and effective growth inhibition at well-tolerated doses, positioning it as a promising candidate for further optimization toward treating human cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/discovery-of-highly-efficacious-crbn-based-kras-degraders-targeting-cancers-with-kras-g12d-and-g12v-mutations/364154/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/discovery-of-highly-efficacious-crbn-based-kras-degraders-targeting-cancers-with-kras-g12d-and-g12v-mutations/364154.png","ImageObject",300,407,{"name":42,"@type":43},"pixelkiddo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic strategy does the document focus on for KRAS-mutant cancers?","Question",{"text":63,"@type":64},"It focuses on induced protein degradation using PROTAC technology to degrade KRAS proteins, aiming to suppress KRAS signaling and related oncogenic functions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is CW-10201 and what did it achieve in cells?",{"text":68,"@type":64},"CW-10201 is a PROTAC KRAS degrader discovered from a novel cereblon ligand. It induced degradation of KRASG12D and KRASG12V mutants at low nanomolar concentrations and produced IC50 values of 2–4 nM for cancer cell growth inhibition.",{"name":70,"@type":61,"acceptedAnswer":71},"How did CW-10201 perform in animal tumor models?",{"text":72,"@type":64},"In mice xenograft models, CW-10201 enabled tumor regression for SW1990 KRASG12D and inhibited tumor growth for SW620 KRASG12V at well-tolerated doses, alongside favorable pharmacokinetic/pharmacodynamic properties.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364154,1790409207,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":104,"preview_page_count":33,"preview_urls":145},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","This article is licensed under CC-BY-NC-ND 4.0  \n[pubs.acs.org/jmc](pubs.acs.org/jmc)  Article   \nDiscovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations  \nChangwei Wang,\\# Prithwish Ghosh,\\# Shicheng Jin,\\# Longchuan Bai,\\# Angelo Aguilar, Donna McEachern, Mi Wang, Qiuxia Li, Bo Wen, Duxin Sun, and Shaomeng Wang*  \n Cite This: J. Med. Chem. 2026, 69, 20520−20539  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: KRAS G12D and G12V mutants account for >50% of human cancers carrying a mutated KRAS protein, and targeting KRAS proteins by induced protein degradation represents an attractive cancer therapeutic strategy. Herein, we present the design, synthesis, and evaluation of PROTAC KRAS degraders using a novel cereblon ligand, which led to the discovery of CW-10201 as a promising KRAS degrader. CW-10201 effectively induced degradation of KRASG12D and KRASG12V mutants at low nanomolar concentrations in cells and attained IC50 values of 2−4 nM in inhibition of cell growth in cancer cell lines carrying KRASG12D or KRASG12V mutation. It demonstrated excellent pharmacokinetic and pharmacodynamic properties in mice. CW-10201 was capable of attaining tumor regression in the SW1990 KRASG12D mutated xenograft tumor model and effectively inhibited tumor growth in the SW620 KRASG12V xenograft tumor model in mice at well-tolerated doses. CW-10201 represents a promising KRASG12D and KRASG12V degrader for extensive evaluation and optimization for the treatment of human cancers.  \n■ INTRODUCTION  \nKRAS is one of the most frequently mutated oncogenes inhuman cancers, playing a critical role in cancer growth, progression and metastasis. KRAS mutations occur in more than 200,000 new cancer cases annually in the United States alone,1 and are found globally in approximately 20% of all human cancers.2 Despite being among the first oncogenes discovered, KRAS has long been considered “undruggable”because of its shallow binding pocket, extremely high affinity for GTP, and the rapid cycling between its active GTP-bound (ON) and inactive GDP-bound (OFF) states.3 After more than three decades of efforts, a major breakthrough was made by Shokat and colleagues on the discovery of small-molecule inhibitors ofKRASG12C targeting the “switch II” pocket,4 which paved the way for the clinical development and ultimate FDA approvals of two KRASG12C inhibitors, namely Sotorasib5 and Adagrasib.6 However, since the G12C mutation represents only about 12% of all KRAS mutations in cancer patients,7 there is an urgent need to develop agents to target other KRAS mutations, particularly KRASG12D and KRASG12V, which  \ntogether account for more than half (52.2%) of all KRASdriven cancers.8  \nIntense research efforts in recent years have now led to the development of small-molecule inhibitors targeting other KRAS mutations. MRTX1133 was designed as the first-inclass selective KRASG12D inhibitor based upon Adagrasib.9 Although the clinical development of MRTX1133 was discontinued due to pharmacokinetic challenges, the preclinical data for MRTX1133 nevertheless demonstrated the feasibility of targeting KRASG12D and potentially other KRAS mutations.10 Indeed, based upon the chemical structure of MRTX1133, different classes of KRASG12D have been discovered and a number of them have been advanced into  \n\n| Received: April 10, 2026\u003Cbr>Revised: July 30, 2026\u003Cbr>Accepted: August 4, 2026\u003Cbr>Published: August 18, 2026 | |\n| --- | --- |\n\n© 2026 The Authors. Published by American Chemical Society  \n20520  \n[https://doi.org/10.1021/acs.jmedchem.6c01](https://doi.org/10.1021/acs.jmedchem.6c01)153  \nJ. Med. Chem. 2026, 69, 20520−20539  \nFigure 1. Chemical structures of representative “molecular glue” pan-KRAS inhibitor RMC-6236 ( 1),36 KRASG12C inhibitor divarasib (2), KRASG12D inhibitor MRTX1133 (3),9 and KRAS","cbCaifXuPDCJWwmQ","https://ap.wps.com/l/cbCaifXuPDCJWwmQ","pdf",5584493,"English","# ABSTRACT\n# INTRODUCTION","[{\"question\":\"What therapeutic strategy does the document focus on for KRAS-mutant cancers?\",\"answer\":\"It focuses on induced protein degradation using PROTAC technology to degrade KRAS proteins, aiming to suppress KRAS signaling and related oncogenic functions.\"},{\"question\":\"What is CW-10201 and what did it achieve in cells?\",\"answer\":\"CW-10201 is a PROTAC KRAS degrader discovered from a novel cereblon ligand. It induced degradation of KRASG12D and KRASG12V mutants at low nanomolar concentrations and produced IC50 values of 2–4 nM for cancer cell growth inhibition.\"},{\"question\":\"How did CW-10201 perform in animal tumor models?\",\"answer\":\"In mice xenograft models, CW-10201 enabled tumor regression for SW1990 KRASG12D and inhibited tumor growth for SW620 KRASG12V at well-tolerated doses, alongside favorable pharmacokinetic/pharmacodynamic properties.\"}]","Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations | PDF",1790156111,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b08cea6a0afd0015679b85abc8a421ce.webp",983,1296,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e0109abb061cf8705abc55405a904a6.webp",982,1295,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/523a88aa795806c4e693f14be9ed24e9.webp",981,1293,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79f3fa833ada67440300b7c3c4772c65.webp",980,1292]